Table 1 Human melanoma cell lines used in the present study, with reference to the mutational state

A375

BRAF CDKN2A CDKN2A

c.1799 T > A c.181G > T c.205G > T

p. V600E p.E61* p.E69*

16,801,397 7,923,152

A375M

BRAF

c.1799 T > A

p. V600E

25,684,511

ME 665

NRAS

c.182A > G

p.Q61R

8,032,213

Mel 397

BRAF

p. V600E

MEL 501

NRAS BRAF

c.35G > A c.1799 T > A

p.G12D p.V600E

24,838,835 15,467,732

MeWo

CDKN2A TP53 TP53

c.238C > T c.772G > A c.949C > T

p.R80* p.E258K p.Q317*

7,478,563 11,096,420

Preyer

n/a

n/a

n/a

n/a

SK-MEL-110

TP53

n/a

n/a

16,267,831

SK-MEL-28

BRAF TP53 CDK4

c.1799 T > A c.434 T > C c.70C > T

p. V600E p. L145R p.R24C

16,170,021 23,856,246 23,856,246

SK-MEL-30

NRAS CDKN2A

c.181C > A c.341C > T

p.Q61K p.P114L

10,766,161 8,895,759